Oxford Biomedica Enhances Board, Fuels Innovation
Company Announcements

Oxford Biomedica Enhances Board, Fuels Innovation

Oxford BioMedica (GB:OXB) has released an update.

Oxford Biomedica, a leader in cell and gene therapy manufacturing, announced the appointment of Heather Preston as Non-Executive Director to Aligos Therapeutics. The company, recognized for its expertise in viral vectors and innovative bioprocessing technologies, plays a crucial role in partnering with major biotech firms. With over 25 years’ experience, Oxford Biomedica continues to impact the delivery of life-changing therapies worldwide.

For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskOxford Biomedica Grants Share Options to Key Personnel
TipRanks UK Auto-Generated NewsdeskOxford Biomedica Announces Total Voting Rights Update
TipRanks UK Auto-Generated NewsdeskOxford BioMedica Sees Shift in Voting Rights
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App